Acompanhamento farmacoterapêutico de pacientes com Transtorno de Déficit de Atenção e/ou Hiperatividade em uso de Metilfenidato

Abstract

Attention Deficit / Hyperactivity Disorder (ADHD) is considered the most common neuropsychiatric disorder and it is socially important in children and adolescents at school age. Currently, pharmacological treatment with psychostimulants is recommended as first choice for children over 6 years. This article has shown the socio-demographic, socioeconomic and pharmacotherapeutic profile of patients with ADHD methylphenidate registered members in pharmaceutical care program of a center of medical specialties fortress. They were identified and classified the problems related to medicine in addition to the adverse reactions associated with the use of methylphenidate. This is an observational, descriptive and longitudinal carried out from December 2013 to November 2014 using as a data collection instrument of a structured form called Pharmacotherapeutic Tracking Sheet in which are contained patient information, prescription medications, adverse reactions to , alerts and performed guidelines. This study showed that the majority were male (86.27%) and less than one year treatment time: one to six months 18 (35.29%) patients and 11 (21.57%) patients treatment with six months to a year. The most commonly encountered subtype was the combined, represented by 21 (56.76%) patients who delivered the scales of parents and teachers duly completed (n = 37). As most prevalent comorbid disorder desafiador- the opponent TOD in 12 (32.44%) patients. The pathology more described in the patient's family was hypertension, followed by depression and heart disease. Most lives with his family of origin or post-divorce, had family income less than two minimum wages (72.55%) and three or four dependent family income (64.71%). Regarding the profile of caregivers it was found that most are female 92.16% and low education. Regarding the pharmacological treatment could be observed most were of polymedication (60.77%). The characterization of problems related to medicine showed that adverse reactions were the leading cause of health problems of patients (65.28%). The incidence of the most prevalent adverse reactions were insomnia (19.15%) and loss of appetite (19.15%). The results showed the socio-demographic, socioeconomic and pharmacotherapeutic profiles of ADHD patients treated at a specialty center showing the main problems related to pharmacotherapy with methylphenidate. Such data can serve as a basis for future interventions in the treatment of these patients.